The TMUH Center for Reproductive Medicine, headed by Professor Tzeng Chii-Ruey, was established in 1991. Using advanced reproductive technologies, this center has helped more than 20,000 infertile couples in the last two decades. Our team of leading physicians and technicians are known for facilitating advanced medical treatments and state-of-the-art services with personal attention and a caring touch. The center enjoys the nations highest success rate for infertility treatment.

    The centers innovative research consistently sets the landmark for fertility treatment in Taiwan . In 1991, the hospitals first test-tube baby was born. In 1993, the center successfully performed the nations first microsurgical epididymal sperm aspiration. In 1995, the first Intracytoplasmic Sperm Injection case led to a successful birth in the hospital. In 1996, the first life birth of frozen embryo was born after thawing. In 1999, the center became Taiwan s first center for reproductive medicine to pass the ISO 9002 Health Mark. The center was awarded the 1999 Gold Prize for National Biotechnology and Medicine Care Quality. After further research and development of the Assisted Reproduction Technique, in 2001 the center pioneered Autologous Mitochondrial Transfer to bring into the world a healthy baby. Significantly, this technology gives great hope in the problem of ovarian aging.

    Every year, nearly 2,000 infertile couples look to the Center for Reproductive Medicine at Taipei Medical University Hospital for help. Among them, about 30% are women in their 40s. Among women over age 30 who suffer from these unknown causes, 90% are infertile because of endometriosis. Endometriosis can be classified into 4 stages according to the size of affected areas and degree of severity; its symptoms include dysmenorrhea and diarrhea before or after menstruation. Mild endometriosis often has no symptoms, or at least undetectable symptoms. Yet regardless of level of severity, endometriosis may cause infertility, so it is crucial for these patients to receive immediate medical attention to determine treatment to assist in conception.

    According to clinical research data on 451 patients collected by the Center for Reproductive Medicine, at the mild endometriosis stage I/II, after being treated with GnRHa, the pregnancy rate is 25% (55/220) using AIH technology. If the patient receives a second treatment after one month's recess, the pregnancy rate is 37.5% (15/40). The pregnancy rate for patients who proceed directly to ovarian stimulation and then artificial insemination without treatment is 13.6% (26/191). By comparison, the statistical differences are significant among these groups.

    For 342 patients with mild endometriosis at stage I/II, with application of GnRHa treatment and later IVF technology, the pregnancy rate is 37.8 % (65/172). Compared to the pregnancy rate of untreated patients (18.2% (31/170), p<0.05), the centers treatment for endometriosis clearly contributed to the successful increase in rate of pregnancy.